> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# HPV-cytology co-testing is not cost-effective in Korean cervical cancer screening
- URL: https://www.coios.me/hpv-cytology-co-testing-is-not-cost-effective-in-korean/
- Published: 2026-11-21T13:15:05.000Z
- Updated: 2026-11-21T16:30:11.000Z
- Description: HPV-cytology co-testing cost 100.5 to 118.4 million won per QALY over biennial cytology, 3.4 to 3.9 times Korea's threshold.
- Author: Daniel Ryan
- Tags: Data, models and systems, Value in health, Cancer, South Korea, #peer-reviewed, #new, #item, #source-2026-11, #score-75

A Markov model compared no screening, cytology and HPV-cytology co-testing across 30 strategies in Korean women aged 20 and over. Biennial cytology cost 1.8 million won per QALY versus no screening, against a 30 million won threshold. Only 4 of 26 co-testing strategies were on the efficiency frontier, none of them cost-effective. Against biennial cytology, they cost 100.5 to 118.4 million won per QALY. Biennial cytology was optimal in 99.6% of probabilistic simulations. The results are modelled estimates, calibrated to registry incidence and tied to current Korean prices.

*Why it is interesting: Even the most efficient co-testing strategy cost over three times Korea's threshold per QALY gained. The model also names the HPV test price at which that strategy's verdict would change.*

Source

[Journal of Gynecologic Oncology, 20 November 2026](https://doi.org/10.3802/jgo.2027.38.e45?ref=coios.me)

DOI

10.3802/jgo.2027.38.e45

Type

Peer-reviewed article

Design

Markov model cost-utility analysis of 30 cervical screening strategies, women aged 20+, lifetime horizon, Korean healthcare system perspective, calibrated to Korea Central Cancer Registry incidence

Verdict

New finding

Driver

[Value in health](https://www.coios.me/d-health-economics/)

Driver

[Cancer](https://www.coios.me/d-cancer/)